Here, we assessed the altered metabolism of aggressive CLL by initially focusing on B cells that overexpress the metabolic marker UGT2B17, which is characteristic of a more aggressive disease and associated with poor survival outcomes.21, 22, 23. This evidence concerns the gene UGT2B17 and B-cell chronic lymphocytic leukemia.